Alexandria Real Estate Equities
ARE
$121.90
Share price
0.85%
Change (1 day)
-37.02%
Change (1 year)
Categories
Alexandria Real Estate Equities, Inc. is a real estate investment trust that invests in office buildings and laboratories.
Market capitalization of Alexandria Real Estate Equities (ARE)
Market cap: $21.09 Billion
As of March 2023 Alexandria Real Estate Equities has a market cap of $21.09 Billion. This makes Alexandria Real Estate Equities the world's 803th most valuable company by market cap according to our data. The market capitalization, commonly called market cap, is the total market value of a publicly traded company's outstanding shares and is commonly used to measure how much a company is worth.
Market cap history of Alexandria Real Estate Equities from 2001 to 2023
End of year Market Cap
| Year | Market cap | Change |
|---|---|---|
| 2023 | $21.09 B | -11.73% |
| 2022 | $23.90 B | -32.17% |
| 2021 | $35.23 B | 46.52% |
| 2020 | $24.04 B | 23.21% |
| 2019 | $19.51 B | 52.57% |
| 2018 | $12.79 B | 1.6% |
| 2017 | $12.59 B | 42.67% |
| 2016 | $8.82 B | 34.62% |
| 2015 | $6.55 B | 3.37% |
| 2014 | $6.34 B | 40.06% |
| 2013 | $4.52 B | 3.28% |
| 2012 | $4.38 B | 2.6% |
| 2011 | $4.27 B | 6.11% |
| 2010 | $4.02 B | 42.85% |
| 2009 | $2.81 B | 44.95% |
| 2008 | $1.94 B | -39.48% |
| 2007 | $3.21 B | 10.31% |
| 2006 | $2.91 B | 61.24% |
| 2005 | $1.80 B | 23.89% |
| 2004 | $1.45 B | 30.74% |
| 2003 | $1.11 B | 37.99% |
| 2002 | $0.80 B | 20.25% |
| 2001 | $0.67 B |
End of Day market cap according to different sources
On Mar 19th, 2023 the market cap of Alexandria Real Estate Equities was reported to be:
$20.92 Billion
$20.92 Billion
$20.92 Billion
$20.92 Billion
Market capitalization for similar companies or competitors
| Name | Market cap | Market cap differencediff. | Country |
|---|---|---|---|
 Pfizer PFE | $230.85 B | 994.15% | 🇺🇸 USA |
 Eli Lilly LLY | $318.04 B | 1,407.35% | 🇺🇸 USA |
 Amgen AMGN | $127.94 B | 506.38% | 🇺🇸 USA |
 Gilead Sciences GILD | $102.36 B | 385.15% | 🇺🇸 USA |
 Illumina ILMN | $34.78 B | 64.87% | 🇺🇸 USA |
 Bristol-Myers Squibb BMY | $142.33 B | 574.58% | 🇺🇸 USA |
 Alnylam Pharmaceuticals
ALNY | $23.80 B | 12.83% | 🇺🇸 USA |